Abbvie receives FDA approval for Rinvoq to treat active Psoriatic Arthritis

On December 14th, Abbvie announced that the U.S. Food and Drug Administration (FDA) has approved RINVOQ® (upadacitinib; 15 mg, once daily) for the treatment of adults with active psoriatic arthritis (PsA) who have had an inadequate response or intolerance to one or more tumor necrosis factor (TNF) blockers.1

Click the link for more information.